Mucoadhesive Drug Delivery Systems for Oral Chronic Inflammatory Mucosal Diseases. The Future is Already Present. A Systematic Review.

IF 2.9 3区医学 Q1 DENTISTRY, ORAL SURGERY & MEDICINE

Oral diseases Pub Date : 2025-07-23 DOI:10.1111/odi.70042

M E Mauceri, M Coppini, V De Caro, G Di Prima, R Mauceri, V Panzarella, G Giuliana, G Campisi

{"title":"Mucoadhesive Drug Delivery Systems for Oral Chronic Inflammatory Mucosal Diseases. The Future is Already Present. A Systematic Review.","authors":"M E Mauceri, M Coppini, V De Caro, G Di Prima, R Mauceri, V Panzarella, G Giuliana, G Campisi","doi":"10.1111/odi.70042","DOIUrl":null,"url":null,"abstract":"Background: Oral lichen planus (OLP) and recurrent aphthous stomatitis (RAS) are considered the most painful oral inflammatory diseases, with high global prevalence and significant impacts on patients' quality of life. In the last decades, researchers have been exploring mucoadhesive drug delivery systems (MDDS) to improve drugs safety and efficacy through optimized formulations for enhancing patients compliance while addressing the limitations of semisolid products.Objective: To assess the clinical efficacy of different MDDS (e.g., tablets, films, and patches) in treating OLP or RAS by a revision of the literature.Methods: According to PRISMA guidelines, the study assessed the remission of signs and symptoms in terms of decreasing burning sensation, pain severity, and lesion size. The protocol was registered on the PROSPERO database (CRD42024603173) and records identified by Medline/PubMed/Scopus.Results: Thirteen observational studies involving humans affected by OLP or RAS were included. The absence of standardized therapies in terms of MDDS, drug, and dosing regimen was highlighted. All MDDS offered several benefits, including prolonged drug release, protection from mechanical irritation, and pain and inflammation reduction. MDDS improved patients' adherence by minimizing daily applications and systemic side effects.Conclusions: MDDS may represent a promising option for both OLP and RAS treatments, addressing key limitations of traditional formulations.","PeriodicalId":19615,"journal":{"name":"Oral diseases","volume":" ","pages":""},"PeriodicalIF":2.9000,"publicationDate":"2025-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oral diseases","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/odi.70042","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"DENTISTRY, ORAL SURGERY & MEDICINE","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Oral lichen planus (OLP) and recurrent aphthous stomatitis (RAS) are considered the most painful oral inflammatory diseases, with high global prevalence and significant impacts on patients' quality of life. In the last decades, researchers have been exploring mucoadhesive drug delivery systems (MDDS) to improve drugs safety and efficacy through optimized formulations for enhancing patients compliance while addressing the limitations of semisolid products.

Objective: To assess the clinical efficacy of different MDDS (e.g., tablets, films, and patches) in treating OLP or RAS by a revision of the literature.

Methods: According to PRISMA guidelines, the study assessed the remission of signs and symptoms in terms of decreasing burning sensation, pain severity, and lesion size. The protocol was registered on the PROSPERO database (CRD42024603173) and records identified by Medline/PubMed/Scopus.

Results: Thirteen observational studies involving humans affected by OLP or RAS were included. The absence of standardized therapies in terms of MDDS, drug, and dosing regimen was highlighted. All MDDS offered several benefits, including prolonged drug release, protection from mechanical irritation, and pain and inflammation reduction. MDDS improved patients' adherence by minimizing daily applications and systemic side effects.

Conclusions: MDDS may represent a promising option for both OLP and RAS treatments, addressing key limitations of traditional formulations.

查看原文本刊更多论文

口腔慢性炎症性粘膜疾病的黏附给药系统。未来已经存在。系统评价。

背景：口腔扁平苔藓（OLP）和复发性口疮性口腔炎（RAS）被认为是最痛苦的口腔炎症性疾病，全球患病率高，严重影响患者的生活质量。在过去的几十年里，研究人员一直在探索黏附给药系统（MDDS），通过优化配方来提高药物的安全性和有效性，以提高患者的依从性，同时解决半固体产品的局限性。目的：通过文献复习，评价不同MDDS（如片剂、贴片、贴片）治疗OLP或RAS的临床疗效。方法：根据PRISMA指南，本研究从灼烧感、疼痛严重程度和病变大小等方面评估症状和体征的缓解情况。该协议已在PROSPERO数据库（CRD42024603173）和Medline/PubMed/Scopus检索的记录中注册。结果：纳入了13项涉及OLP或RAS患者的观察性研究。强调了在MDDS、药物和给药方案方面缺乏标准化的治疗方法。所有MDDS都有一些好处，包括延长药物释放时间，防止机械刺激，减轻疼痛和炎症。MDDS通过减少每日应用和全身副作用来改善患者的依从性。结论：MDDS可能是OLP和RAS治疗的一个有希望的选择，解决了传统配方的主要局限性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Oral diseases 医学-牙科与口腔外科

CiteScore

7.60

自引率

5.30%

发文量

325

审稿时长

4-8 weeks

期刊介绍： Oral Diseases is a multidisciplinary and international journal with a focus on head and neck disorders, edited by leaders in the field, Professor Giovanni Lodi (Editor-in-Chief, Milan, Italy), Professor Stefano Petti (Deputy Editor, Rome, Italy) and Associate Professor Gulshan Sunavala-Dossabhoy (Deputy Editor, Shreveport, LA, USA). The journal is pre-eminent in oral medicine. Oral Diseases specifically strives to link often-isolated areas of dentistry and medicine through broad-based scholarship that includes well-designed and controlled clinical research, analytical epidemiology, and the translation of basic science in pre-clinical studies. The journal typically publishes articles relevant to many related medical specialties including especially dermatology, gastroenterology, hematology, immunology, infectious diseases, neuropsychiatry, oncology and otolaryngology. The essential requirement is that all submitted research is hypothesis-driven, with significant positive and negative results both welcomed. Equal publication emphasis is placed on etiology, pathogenesis, diagnosis, prevention and treatment.